The company's ability to write DNA on silicon chips combined with proprietary software and e-commerce platform creates a highly scalable manufacturing process with significant cost advantages. Twist is targeting adjusted EBITDA breakeven by Q4 fiscal 2026 while driving toward sustained and profitable growth.
Cyborg Score Rationale
Twist reported 17% revenue growth to $103.7M in Q1 FY2026 with 52% gross margin and is benefiting from AI-enabled discovery trends. The company targets EBITDA breakeven in Q4 2026 with gross margins expected above 52%. Strong tailwinds from AI adoption and expanding customer base offset profitability concerns.
Top Insights
DNA Synthesis & Protein Solutions segment saw 27% growth driven by AI
Customer base has grown to over 3,800 annually, reflecting market penetration across diverse industries
FY26 guidance raised to $435-$440M revenue representing approximately 16% growth YoY
Barclays maintained overweight rating acknowledging Twist's competitive edge in AI-driven drug discovery
Named Competitors
DNA Synthesis Platform — Synthetic biology and cell programming